Ion Beam Applications SA
XBRU:IBAB
Ion Beam Applications SA
Research & Development
Ion Beam Applications SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ion Beam Applications SA
XBRU:IBAB
|
Research & Development
-€62.3m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Nyxoah SA
XBRU:NYXH
|
Research & Development
-€14.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Sequana Medical NV
XBRU:SEQUA
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ion Beam Applications SA
Glance View
Ion Beam Applications SA engages in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. The company is headquartered in Louvain-La-Neuve, Brabant-Wallon. IBA is also active in the sterilization and ionization field. The firm operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
See Also
What is Ion Beam Applications SA's Research & Development?
Research & Development
-62.3m
EUR
Based on the financial report for Jun 30, 2025, Ion Beam Applications SA's Research & Development amounts to -62.3m EUR.
What is Ion Beam Applications SA's Research & Development growth rate?
Research & Development CAGR 5Y
-12%
Over the last year, the Research & Development growth was -22%. The average annual Research & Development growth rates for Ion Beam Applications SA have been -17% over the past three years , -12% over the past five years .
